VYNT Vyant Bio, Inc.

StemoniX Inc. provides IPS-based platforms for pharma and research institutions. The company offers StemoniX, a platform that focuses on printing of stem-cell derived human tissue for custom drug discovery and personalized medicine. Its solution enables scaled 3-D printing of living cells into larger form factors for heart disease, dementia, breast cancer, autism, ALS, and more. The company was incorporated in 2014 and is headquartered in Minneapolis, Minnesota with an additional office in LA Jolla, California.  This company has other shares of common stock that are publicly traded. See the "related symbols" tab.

As of 04/14/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Index country:  USA
Country of incorporation:  USA
IPO date:  04/05/2013
Outstanding shares:  11,007,186
Average volume:  1,049,761
Market cap:   $40,176,229
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    92942V109
ISIN:        US92942V1098
Sedol:      BMV31S6
Valuation   (See tab for details)
PE ratio:   -12.15
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy